Revista nº 817

Tratamiento de la COVID-19 | Quintanilla Carrillo B, et al. 182 Actual Med.2023;108(817):166-184 17. Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Mon- tejano R, et al; GS-US-540-5773 Investigators. Remdesi- vir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 Nov 5;383(19):1827-1837. 18. Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Ca- ttelan AM, Soriano Viladomiu A, et al; GS-US-540-5774 Investigators. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 Sep 15;324(11):1048-1057. 19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Re- mdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lan- cet. 2020 May 16;395(10236):1569-1578. Erratum in: Lancet. 2020 May 30;395(10238):1694. 20. RECOVERY Collaborative Group. Dexamethasone in Hos- pitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. 21. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al; COALITION COVID-19 Brazil III In- vestigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Seve- re Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1307-1316. 22. Dequin PF, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al; CAPE COVID Trial Group and the CRICS-TriG- GERSep Network. Effect of Hydrocortisone on 21-Day Mor- tality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1298-1306. 23. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on Mortality and Or- gan Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Rando- mized Clinical Trial. JAMA. 2020 Oct 6;324(13):1317- 1329. 24. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al; for the Metcovid Team. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Clin Infect Dis. 2020 Aug 12:ciaa1177. 25. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Be- tween Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020 Oct 6;324(13):1330-1341. 26. Zhao H, Zhu Q, Zhang C, Li J, Wei M, Qin Y, et al. Tocili- zumab combined with favipiravir in the treatment of CO- VID-19: A multicenter trial in a small sample size. Biomed Pharmacother. 2021 Jan;133:110825. 27. Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al; RCT-TCZ-COVID-19 Study Group. Effect of Tocili- zumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 Jan 1;181(1):24-31. 28. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Por- cher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of Tocilizumab vs Usual Care in Adults Hospitali- zed With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 Jan 1;181(1):32-40. Erratum in: JAMA Intern Med. 2021 Jan 1;181(1):144. 29. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Har- vey L, Foulkes AS, et al; BACC Bay Tocilizumab Trial Investi- gators. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10;383(24):2333-2344. 30. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Seve- re Covid-19 Pneumonia. N Engl J Med. 2021 Feb 25:NEJ- Moa2028700. 31. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021 Jan 7;384(1):20-30. 32. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Re- ceptor Antagonists in Critically Ill Patients with Covid-19 Preliminary report. medRxiv 2021. 2021.01.07.21249390. 33. Veiga VC, Prats JAGG, Farias DLC, Rosa RG, Dourado LK, Zampieri FG, et al; Coalition covid-19 Brazil VI Investiga- tors. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021 Jan 20;372:n84. 34. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a rando- mised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-1645. 35. Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H, et al. Anakinra in hospitalized pa- tients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventio- nal study. Int J Infect Dis. 2021 Feb;103:288-296. 36. CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021 Jan 22:S2213-2600(20)30556-7. 37. Entrenas Castillo M, Entrenas Costa LM, Vaquero Ba- rrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al. “Effect of calcifediol treatment and best available the- rapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study”. J Steroid Biochem Mol Biol. 2020 Oct;203:105751.